<a href="https://www.fiercebiotech.com/biotech/chutes-ladders-astrazeneca-adds-fda-cell-and-gene-veteran" hreflang="en">Chutes & Ladders—AstraZeneca adds FDA cell and gene veteran</a>
AstraZeneca has appointed Lola Fashoyin-Aje, a former FDA leader in cell and gene therapy, as its new vice president and head of cell therapy regulatory science and strategy. Additionally, Corrixr Therapeutics has named Hilary Malone as its new CEO, while Capricor Therapeutics has brought in Michael Maurer as chief commercial officer to prepare for the launch of its investigational cell therapy for Duchenne muscular dystrophy.
AstraZeneca's strategic hire of Lola Fashoyin-Aje, a former FDA leader with extensive experience in cell and gene therapies, as vice president of cell therapy regulatory science and strategy, signifies a strong move to bolster their regulatory capabilities in these advanced therapeutic areas. This could be a pivotal moment for AstraZeneca's pipeline, especially for professionals tracking regulatory advancements and strategic leadership changes in biotech companies.